EXELA PHARMA
SpecialtyEXELA PHARMA is a specialty pharmaceutical company focused on Cardiovascular, Gastroenterology, Metabolic. Key products include GLYRX-PF.
EXELA PHARMA's Key Drugs
EXELA PHARMA's core commercial portfolio centers on GLYRX-PF, ELCYS, AKOVAZ, spanning Cardiovascular and Gastroenterology — its most strategically important drugs approved in the last 15 years.
EXELA PHARMA's Recent FDA Approvals
EXELA PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
EXELA PHARMA's Therapeutic Areas
EXELA PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Gastroenterology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EXELA PHARMA's Top Competitors
EXELA PHARMA's closest competitors by therapeutic-area and drug-target overlap include Merck, APOTHECON, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EXELA PHARMA Pipeline Snapshot
Active clinical trials for EXELA PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GLYRX-PF leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (4)
Company Info
- First Approval
- 1984-03-30
- Latest
- 2025-12-22
- Applications
- 22